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Beyond Low-Density Lipoprotein Cholesterol
Defining the Role of Low-Density
Lipoprotein Heterogeneity in Coronary Artery Disease
James O. Mudd, MD,* Barry A. Borlaug, MD,* Peter V. Johnston, MD,* Brian G. Kral, MD, MPH,*
Rosanne Rouf, MD,* Roger S. Blumenthal, MD,* Peter O. Kwiterovich, JR, MD†
Baltimore, Maryland
Recent clinical trials in patients with coronary artery disease (CAD) provide evidence that low-density lipoprotein
cholesterol (LDL-C) levels should be lowered even further to prevent recurrent CAD. However, despite more ag-
gressive interventions for lowering LDL-C levels, the majority of CAD events go undeterred, perhaps related to
the fact that intervention was not started earlier in life or that LDL-C levels represent an incomplete picture of
atherogenic potential. Nevertheless, LDL-C remains the contemporary standard as the primary goal for aggres-
sive LDL reduction. If triglycerides are 200 mg/dl, the measurement of non–high-density lipoprotein choles-
terol (HDL-C) is recommended. Measurement of apolipoprotein (apo)B has been shown in nearly all studies to
outperform LDL-C and non–HDL-C as a predictor of CAD events and as an index of residual CAD risk. This is be-
cause apoB reflects the total number of atherogenic apoB-containing lipoproteins and is a superior predictor of
the number of low-density lipoprotein particles (LDL-P). Estimates of LDL-P and size can also be made by nu-
clear magnetic resonance spectroscopy, density gradient ultracentrifugation, and gradient gel electrophoresis.
Although a number of studies show that such estimates predict CAD, LDL-P, and size often accompany low
HDL-C and high triglyceride levels, and therefore such additional lipoprotein testing has not been recommended
for routine screening and follow-up. Because apoB is a superior predictor of LDL-P, we recommend that apoB
and the apoB/apoA-I ratio be determined after measurement of LDL-C, non–HDL-C, and the ratio of total
cholesterol/HDL-C to better predict CAD and assess efficacy of treatment. (J Am Coll Cardiol 2007;50:
1735–41) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.045(
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Tlevated low-density lipoprotein cholesterol (LDL-C) is a
ell-established independent risk factor for coronary artery
isease (CAD). A number of primary and secondary trials
ave demonstrated that lowering of LDL-C decreases the
ncidence of CAD. These trials have been reviewed in detail
lsewhere (1–4) and include treatment with a fat-modified
iet and therapeutic agents such as inhibitors of 3-hydroxy-
-methylglutaryl coenzyme A reductase (statins), fibrates,
iacin, and bile acid sequestrants. These studies, in aggre-
ate, are the basis for the recommendations of the National
holesterol Education Program (NCEP) that LDL-C be
owered to 100 mg/dl in patients with CAD or CAD risk
quivalents, such as diabetes or peripheral arterial disease.
The HPS (Heart Protection Study) (5), the PROVE-IT
Pravastatin or Atorvastatin Evaluation and Infection Ther-
py) study (6), and the REVERSAL (Reversal of Athero-
clerosis with Aggressive Lipid Lowering) study (7) all
ndicated a significant benefit to lowering LDL-C well
elow 100 mg/dl. The NCEP-Adult Treatment Panel
rom the *Johns Hopkins Ciccarone Preventive Cardiology Center and the †Johns
opkins University Lipid Clinic, Baltimore, Maryland.d
Manuscript received April 30, 2007; revised manuscript received July 16, 2007,
ccepted July 17, 2007.ATP) III guidelines were therefore amended in 2004 by
dding an optional goal of LDL-C 70 mg/dl in patients
ith recent acute coronary syndromes or those otherwise
elt to be at “very high risk” for adverse cardiovascular events
2). Subsequently, the TNT (Treating to New Targets)
tudy (8), with atorvastatin 80 mg/day versus 10 mg/day,
nd ASTEROID (A Study to Evaluate the Effect of
osuvastatin [40 mg/day] on Intravascular Ultrasound-
erived Coronary Atheroma Burden) (9) both supported
he more aggressive treatment of LDL-C to 70 mg/dl.
’Keefe et al. (3) proposed that the threshold for atheroscle-
otic progression may be at an LDL-C level of 70 mg/dl.
Still, despite aggressive use of statins, the majority of
AD events are not prevented (1–8). In the IDEAL
Incremental Decrease in End Points Through Aggressive
ipid Lowering) study, the use of atorvastatin 80 mg/day
ompared with simvastatin 20 mg/day did not result in a
ignificant reduction in the primary outcome of major
oronary events (10). This may be due to the fact that these
tudies were of relatively short duration and in older adults.
he benefit is likely to be greater if intervention is started
arlier in life and continued for a longer time period (11).
he presence of traditional risk factors such as hypertension,
iabetes, obesity, elevated triglycerides (TG), and low high-
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(HDL-C) may also render the
LDL-C intervention less effec-
tive. The influence of nontradi-
tional risk factors such as small,
dense LDL particles, elevated lev-
els of high-sensitivity C-reactive
protein (hs-CRP), lipoprotein
(a) [Lp(a)], homocysteine, and
unknown genetic and environ-
mental risk factors on recurrent
CAD events is not completely
understood (1,2).
Another possible contributory
factor is that LDL-C does not
reflect the atherogenicity of all
of the apolipoprotein (apo)B-
containing lipoproteins nor does
it necessarily represent the total
number of low-density lipopro-
tein particles (LDL-P) or the
distribution of size within those
particles. This is particularly true
if small, dense LDL-P is ele-
ated, leading to an underestimate of LDL-P by LDL-C.
ow HDL-C with a normal LDL-C is often accompanied
y increased small, dense LDL-P (12). Patients with
yper-TG may also have increased small, dense LDL-P,
lacing them at higher CAD risk than those hyper-TG
atients with a normal LDL-P (13). Here we review the
pidemiologic and clinical evidence that determination of
DL-P supplements the LDL-C measurement and has
oth diagnostic and therapeutic implications.
Figure 1 Mechanisms of the Production of the “Dyslipidemic T
An increased flux of free fatty acids (FFA) from adipose tissue can result from insu
hepatic uptake of FFA leads to increased triglyceride (TG), apolipoprotein (apo) B,
cholesteryl esters (CE) from low-density lipoproteins (LDL) and high-density lipopro
LDL and HDL. The TG in the core of LDL and HDL is then hydrolyzed by lipases, pr
the kidney, resulting in low HDL-C levels. HL  hepatic lipase; IDL  intermediate
ferase; LPL  lipoprotein lipase.
Abbreviations
and Acronyms
apo  apolipoprotein
CAD  coronary artery
disease
CE  cholesteryl esters
DGU  density-gradient
ultracentrifugation
GGE  gradient gel
electrophoresis
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
LDL-P  total number of
low-density lipoprotein
particles
Lp(a)  lipoprotein (a)
NMR  nuclear magnetic
resonance
TC  total cholesterol
TG  triglyceridesiochemical Basis of LDL Heterogeneity
ow-density lipoprotein is a heterogeneous group of parti-
les that vary in their core content of cholesterol (12–14). A
reater amount of cholesterol in LDL creates larger, more
uoyant particles (sometimes referred to as LDL subclass A).
lower amount of cholesterol in LDL generates smaller,
enser particles (sometimes referred to as LDL subclass B).
ach LDL particle, regardless of its cholesterol content, has
molecule of apoB for each LDL molecule (13). For 2
atients with the same LDL-C, the one with a preponder-
nce of small LDL particles will have a greater LDL-P,
arry a significantly greater risk of CAD, and may therefore
enefit from more aggressive therapy (12–16).
LDL–IDL–LDL pathway. Alterations in the very-low-
ensity lipoprotein (VLDL)–intermediate-density lipoprotein
IDL)–LDL pathway, whether owing to genetic mutations,
cquired disorders, diet, or other factors, result in variation in
article composition, size, and abundance (12–16) (Fig. 1). For
xample, the metabolic syndrome, diabetes, familial combined
yperlipidemia, and hyperapobetalipoproteinemia (hyper-
poB) are conditions in which increased synthesis and secre-
ion of VLDL leads to the overproduction of small, dense
DL and HDL particles, a combination that increases cardio-
ascular risk (13–17) (Fig. 1). Insulin resistance or a defect in
he normal activity of the acylation stimulatory protein can
ause higher plasma free fatty acid levels, leading to greater
epatic free fatty acid uptake, increased TG production,
ecreased hydrolysis of apoB, and increased production and
ecretion of larger TG-rich VLDL particles (13–17) (Fig. 1).
An increased exchange of TG from VLDL for cholesteryl
ster (CE) in LDL and HDL occurs via the CE transfer
rotein, resulting in cholesterol-depleted TG-enriched li-
istance or a defect in the acylation stimulatory protein (ASP) pathway. Enhanced
ry-low-density lipoprotein (VLDL) production. The TG in VLDL is exchanged for
HDL) by the cholesteryl ester transport protein (CETP), producing CE-depleted
g both small, dense LDL and HDL. Such HDL is more likely to be excreted by
y lipoprotein; IR  insulin resistance; LCAT  lecithin-cholesterol acyltrans-riad”
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October 30, 2007:1735–41 LDL Heterogeneity in CADoproteins that are subsequently converted into smaller, denser
articles by hepatic lipase (Fig. 1). The TG-enriched LDL is
ydrolyzed, leading to increased small, dense LDL-P (15).
he TG-rich HDL is also modified by hepatic lipase, produc-
ng smaller HDL that is cleared more rapidly by the kidneys,
ontributing to lower levels of HDL-C and its major
polipoprotein, apoA-I (Fig. 1). Such abnormalities in the
LDL–IDL–LDL pathway are often manifested by the
yslipidemic triad of hyper-TG, increased small, dense
DL-P, and low HDL-C.
he Contemporary Standards:
DL-C and Non–HDL-C
DL-C. Aggressive reduction of LDL-C is the current
rimary goal of lipid-lowering therapy (1–10). The LDL-C
eflects the cholesterol content of several atherogenic li-
oproteins, including LDL, IDL, and Lp(a). The conven-
ional lipid panel measures levels of total cholesterol (TC),
DL-C, and TG and calculates LDL-C using the Friede-
ald equation (18). To use this formula, the patient must be
asting with a TG level400 mg/dl. As LDL-C nears goal,
he inaccuracies of the Friedewald equation are amplified
19). For example, calculated LDL-C generally underesti-
ates the true concentration of small, dense LDL particles,
specially when the TG level is200 mg/dl (13). Given these
imitations of LDL-C, the NCEP recommended using
on–HDL-C (total cholesterol  HDL-C) as a secondary
arget of therapy when the TG level is 200 mg/dl (1).
on–HDL-C. The non–HDL-C estimates the choles-
erol concentration of all the apoB-containing lipoproteins,
amely VLDL, IDL, LDL, and Lp(a), in contrast to
DL-C, which does not include VLDL-C. The non–
DL-C can be measured nonfasting. If the TG level is
levated to 200 mg/dl, the non–HDL level will reflect the
ncrease in VLDL-C. The non–HDL-C appears superior
o LDL-C estimation in establishing CAD risk and monitor-
ng treatment (20–23). However, lipid levels do not necessarily
quate to lipoprotein particle levels, and non–HDL-C does
ot permit a determination of whether there is also an
ncrease in small, dense LDL-P in the hyper-TG patient.
eyond LDL-C and Non–HDL-C
poB measurement. The apoB level reflects the total
umber of atherogenic apoB-containing lipoproteins, be-
ause each chylomicron, chylomicron remnant, VLDL,
DL, LDL, and Lp(a) particle contains 1 molecule of apoB.
owever, 90% of total plasma apoB is contained within the
DL particles (13). Thus, for a given LDL-C level, a higher
poB level indicates higher LDL-P. Measurement of apoB (as
ell as apoA-I) does not need to be done in the fasting state,
as been standardized by the World Health Organization,
nd is available in most large commercial laboratories (24).
Moreover, apoB has been shown in nearly all studies to
utperform LDL-C and non–HDL-C measurements in car-
iovascular risk stratification (25–30). These include several
l
carge, prospective studies such as AMORIS (Apoprotein-
elated Mortality Risk Study) (29), the Health Professionals
ollow-Up Study (27), the Quebec Cardiovascular Study
25,26), and the study by Moss et al. (30).
Benn et al. (31) recently reported that apoB had a higher
redictive ability than LDL-C for ischemic cardiovascular
isease in 9,231 asymptomatic Danish men and women.
sing receiver-operating characteristic curves, they found
hat the predictive ability of non–HDL-C was similar to
poB. However, the interindividual biological variation for
poB (coefficient of variation [CV] 6.9%) was superior to
on–HDL-C (TC CV 6% plus HDL-C CV 7.1%), indi-
ating that repeated measurements of apoB are more reliable
n a single patient. Apolipoprotein B also appears to be a
etter predictor of subsequent CAD events in patients on
reatment with statins (28,32).
atio of apoB to apoA-I. Results from a number of
pidemiologic studies indicated that the ratio of apoB to
poA-I was the strongest predictor of CAD (28). In both
he placebo and the treatment groups from the AFCAPS/
EXCAPS (Air Force/Texas Coronary Atherosclerosis
revention Study) trial, the apoB/apoA-I ratio was a robust
redictor of CAD (32). Similarly, van Lennep et al. (33)
eported in patients with CAD on statin therapy that only
poB and the apoB/apoA-I ratio predicted myocardial
nfarction and all-cause mortality, whereas LDL-C and TG
id not. In both men and women from the AMORIS
Apolipoprotein-Related Mortality Risk) study, the superi-
rity of the ratio of apoB to apoA-I, compared with the
C/HDL-C ratio, became more obvious as risk of CAD
ncreased (28). In men, the relative risk of CAD increased at
n apoB/apoA-I ratio of 1.0, and the comparative figure for
emales was 0.86 (28). These results in aggregate are not
urprising, given that increased LDL-P is usually accompa-
ied by low HDL and apoA-I (Fig. 1).
The percentile distributions for LDL-C, non–HDL-C,
nd apoB are available from the Framingham Heart Study
23,34,35) (Table 1). For a particular goal for LDL-C
reatment from the NCEP-ATP III (e.g.,100 mg/dl) one
an estimate what the equivalent goal (based on percent
n the population) for apoB might be (e.g., 80 mg/dl)
Table 1). The percentile distributions for HDL-C and
stimated Percentiles ofDL-C, Non–HDL-C, ApoB, and LDL-P
Table 1 Estimated Percentiles ofLDL-C, Non–HDL-C, ApoB, and LDL-P
Percentile
5th 10th 25th 50th 75th 90th 95th
LDL-C (mg/dl) 80 90 110 130 160 180 200
Non–HDL-C
(mg/dl)
110 120 140 160 190 210 230
ApoB (mg/dl) 60 70 80 100 120 140 150
LDL-P (nmol/l) 800 900 1,100 1,400 1,800 2,000 2,100
stimates were derived from the Framingham Heart Study (23,34,36). Men and women were
ombined.
ApoB  apolipoprotein B; LDL-C  low-density lipoprotein cholesterol; LDL-P  total number ofow-density lipoprotein particles; non–HDL-C  total cholesterol  high-density lipoprotein
holesterol.
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LDL Heterogeneity in CAD October 30, 2007:1735–41poA-I in men and women from the Framingham Heart
tudy (35) are also provided in Table 2. We propose that in
ddition to apoB, the ratio of apoB/apoA-I be included as
lternative goals in consensus recommendations for LDL
eduction and HDL increase.
ther assessments of LDL particle number and size.
he LDL-P is determined by the rate at which the LDL
articles are produced and cleared from the circulation
13–16) (Figs. 1 and 2). Furthermore, there are documented
ariations between different ages, genders, and races (36–
8). For a given LDL-C level, an increase in small, dense
DL-P is associated with increased atherogenesis, which
ay explain some of the variation in risk between different
ndividuals and populations (36–38). More direct measures
f LDL-P may help to further delineate the risk of CAD
ttributable to metabolic abnormalities such as diabetes and
he metabolic syndrome (14,16,17).
The direct measurement of LDL-P number and size is
echnically difficult, relatively time consuming, and more
xpensive than apoB measurement. The LDL-P number
nd size have also been assessed by nuclear magnetic
esonance (NMR) spectroscopy, density-gradient ultracen-
rifugation (DGU), or gradient gel electrophoresis (GGE).
recent report found that an assessment of these methods
o determine LDL size agreed poorly (39). The LDL-P
owever, was not evaluated, but the different tests also
eported significant variations in LDL-C, which is what our
urrent treatment guidelines are based upon.
MR spectroscopy. Nuclear magnetic resonance spectros-
opy rapidly determines the sizes and concentrations of 15
ipoprotein subclasses based on the spectral characteristics of
ethyl groups within the lipid molecules and the difference
n size of the lipoprotein particles (12). The LDL-P by
MR includes IDL and 3 LDL subclasses. Nuclear mag-
etic resonance has been validated against existing methods
f lipoprotein subclass determination (12); however, there is
o international standardization program. Nuclear magnetic
esonance was only performed by LipoScience (Raleigh,
orth Carolina).
The LDL-P appears to be a particularly strong predictor
f CAD in women. In the prospective CHS (Cardiovascular
ealth Study) (37), NMR-determined LDL-P and small
stimated Percentiles of HDL-Cnd ApoA-I Levels (mg/dl) in Men and Women
Table 2 Estimated Percentiles of HDL-Cand ApoA-I Levels (mg/dl) in Men and Women
Percentile
5th 10th 25th 50th 75th 90th 95th
HDL-C
Men 28 31 37 43 51 61 67
Women 35 39 46 55 66 77 84
ApoA-I
Men 92 99 114 130 153 178 196
Women 107 116 132 154 181 206 224
stimates were derived from the Framingham Heart Study (35).
ApoA-I  apolipoprotein A-I; HDL-C  high-density lipoprotein cholesterol.DL particle size predicted incident CAD, primarilymong elderly women. The LDL-P remained significant,
ven after adjustment for traditional risk factors, whereas
DL particle size did not. Mackey et al. (40) found that
DL-P, small, dense LDL, and large VLDL were posi-
ively associated with coronary artery calcification in healthy
ostmenopausal women, after adjustment for age, systolic
lood pressure, current smoking, LDL-C, HDL-C, and
G. Blake et al. (15) found that LDL-P in healthy women
as independently predictive of future myocardial infarc-
ion, even after adjustment for the ratio of TC to LDL-C,
poB, and hs-CRP.
Rosenson et al. (41) measured LDL and HDL particle
ize and concentration by NMR spectroscopy in frozen
lasma samples of placebo- and pravastatin-treated subjects.
hereas lipid levels did not predict angiographic progres-
ion of CAD, LDL-P strongly correlated with progression
41).
In the MESA (Multiethnic Study of Atherosclerosis)
tudy, Mora et al. (42) studied the association of LDL-P
nd particle size by NMR with carotid intima-media
hickness (IMT) in over 5,000 apparently healthy indi-
iduals. When controlling for traditional CAD risk
actors and LDL subclass correlation, both large and
mall LDL-P, but not LDL size, were significantly
ssociated with carotid IMT.
Figure 2 Proposed Biochemical and Cellular
Mechanisms of Enhanced Small, Dense LDL
Increased small dense low-density lipoprotein (LDL) production, combined with
a lower affinity of small, dense LDL for the low-density lipoprotein receptor
(LDL-R) and a longer residence time in plasma, leads to an increased number
of small, dense LDL particles. The increased small, dense LDL cross the arte-
rial wall more readily, bind more avidly to proteoglycans in the intimal matrix,
and are more easily oxidized, characteristics all conducive to atherogenesis
(16). Small, dense LDL promotes endothelial cell dysfunction, inducing greater
production of plasminogen activator inhibitor (PAI)-I and thromboxane A (TXA ).2 2
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October 30, 2007:1735–41 LDL Heterogeneity in CADIn the prospective EPIC (European Prospective Investi-
ation Into Cancer and Nutrition)-Norfolk study (22) in
5,663 subjects, both LDL-P, as assessed by NMR, and
on–HDL-C were more closely associated with CAD than
DL-C. After HDL-C and TG levels were accounted for,
DL-P lost its discriminative power over LDL-C. Consis-
ent with the MESA study, the EPIC-Norfolk study also
ound that LDL size was not predictive of CAD after
djustment for LDL-P. These results argue against the
outine implementation of determining LDL-P number
nd size by NMR for CAD risk assessment. However, the
act that patients with low HDL-C and/or higher TG often
ave elevated numbers of LDL-P, without having high
DL-C, may enable their LDL-related CAD risk to be
anaged more effectively. Although data from clinical
ntervention studies (see subsequent text) support LDL-P
y NMR as an alternative treatment target (but not superior
o apoB), the value of LDL-P monitoring as an additional
reatment target beyond LDL-C needs to be assessed in
ntervention trials.
GU. In DGU, lipoprotein fractions from a density gra-
ient are eluted systematically and the cholesterol content
etermined. The method allows an estimate of the relative
istribution of cholesterol but not particle number within
he IDL and LDL subclasses. Evidence from several angio-
raphic trials using DGU indicated that treatment benefit is
elated to a significant decrease in small, dense LDL-C
43–45), independent of other lipid and nonlipid risk
actors.
The Vertical Auto Profile II (Atherotech, Birmingham,
labama) is a DGU-based test that determines the choles-
erol content of VLDL, LDL, and HDL subclasses, Lp(a),
nd patterns of LDL size (LDL subclass A, AB, or B) (46).
GE. The GGE also determines the size and estimates
he relative concentration of lipoprotein subclasses. Seven
ifferent LDL subclasses are identified by GGE and their
oncentration is estimated by densitometry. Such testing is
vailable from the Berkeley HeartLab (Burlingame,
alifornia).
In the Stanford Study (47) and the Physicians’ Health
tudy (48), small, dense LDL by GGE predicted CAD but
as not independent of the TC/HDL-C ratio and nonfast-
ng TG, respectively. The SCRIPS (Stanford Coronary
isk Intervention Project) (49) trial, a 4-year angiographic
rial, found that small, dense LDL by GGE predicted both
he progression of stenosis in the control group and the vast
ajority of angiographic benefit in the group on multifac-
orial intervention. Those with predominantly large LDL,
espite the same LDL-C reduction as those with small,
ense LDL, showed angiographic progression at the same
ate as the usual care (control) group.
reatment Implications of LDL Heterogeneity
lthough hyper-TG and reduced HDL-C, commonly ob-
erved in diabetes (16) and the metabolic syndrome (17), are ceflected in the conventional lipid profile, calculated
DL-C often does not reflect small, dense LDL-P in such
atients (13). Recognition of this is important, because
ncreased small, dense LDL-P due to enhanced production
f TG-rich VLDL appears to be the single most frequent
yslipidemia in patients with premature CAD (13–16).
hus, a low or normal LDL-C level may result in a less
ggressive approach than may be clinically indicated, par-
icularly in the patient who may benefit more from com-
ined lipid-altering therapy.
Multiple biochemical and cellular mechanisms of athero-
enic small, dense LDL particles have been proposed (16) (Fig.
). It is still incompletely resolved whether risk of CAD is
imply related to LDL-P per se, or whether LDL size is also
n independent predictor of CAD (see preceding text). Al-
hough studies have demonstrated improvement in LDL
article size distribution with pharmacologic intervention, it
emains to be established whether risk stratification based
n LDL size by “advanced” or additional lipoprotein testing
s sufficiently additive to merit a change in management
trategies.
ltering LDL Particle Number and Size
tatins are the most potent class of drugs to reduce LDL-P,
ncluding small, dense LDL-P. Higher doses of the more
owerful statins may also decrease VLDL production,
eading to a small shift from small, dense to larger LDL
articles. Both niacin and fibrates convert small, dense LDL
nto larger, more buoyant LDL.
Although LDL-P clearly predicts CAD events, it is
nclear if altering LDL size decreases CAD events inde-
endent of any effect on lowering LDL-P. In the VA-HIT
Veterans Affairs High-Density Lipoprotein Intervention
rial) study (50) subjects with low HDL-C and average
DL-C treated with gemfibrozil had a significant decrease
n CAD events compared with placebo, an effect propor-
ional to the increase in HDL-C, because LDL-C was not
ecreased with gemfibrozil. Using NMR, Otvos et al. (51)
eported that gemfibrozil lowered small, dense LDL-P,
hereby increasing total LDL size. Total HDL-P, particu-
arly HDL-3, increased with gemfibrozil. These changes in
article composition independently decreased risk of new
AD events and explained a significant amount of the
enefit of gemfibrozil in the VA-HIT study.
Additionally, the DAIS (Diabetes Atherosclerosis In-
ervention Study) trial (52) showed that patients with
ype 2 diabetes treated with fenofibrate had a significantly
ecreased rate of angiographic CAD progression and a
reater increase in LDL size compared with placebo
ontrols. In a substudy, Vakkilainen et al. (53) found that
mall LDL size was associated with greater CAD pro-
ression, regardless of treatment group, and that fenofi-
rate produced a greater increase in LDL particle size
ompared with placebo. In contrast, the FIELD (Feno-
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LDL Heterogeneity in CAD October 30, 2007:1735–41brate Intervention and Event Lowering in Diabetes) study
54) was associated with a nonsignificant 11% reduction in the
rimary end point (coronary heart disease death and non-
atal myocardial infarction); however, changes in LDL-P
nd LDL particle size were not reported.
erspectives and Future Directions
he evidence supporting the incremental value of measur-
ng apoB is strong and internally consistent. The Thirty-
erson/Ten-Country Panel has proposed that evidenced-
ased guidelines endorse alternatives such as apoB in both
en and women (28), a recommendation further supported
y the results of the large Copenhagen City Heart Study
31). Statin-treated patients may have a proportionally
igher apoB than LDL-C, indicating that too many
DL-P are still present. Those patients will require further
ntervention, often in the form of combined lipid-altering
rugs. For patients with CAD, CAD risk equivalents, or a
igh risk of CAD, a more aggressive LDL-C goal of 70
g/dl should be considered. This goal is in fact less than the
fth percentile for LDL-C. The recently proposed goal
f 80 mg/dl for apoB in such high-risk patients is about
he 25th percentile. Although it is not certain what the
quivalent goal of apoB should be when the LDL-C goal is
70 mg/dl, the equivalent percentile for apoB is 60 mg/dl.
Recent evidence indicates that non–HDL-C and LDL-P
lso provide additional prognostic information over
DL-C. Population-based percentiles for LDL-C, non–
DL-C, apoB, and LDL-P are available from the Fra-
ingham Heart Study (36). Alternative goals for LDL-P as
ell as apoB related to current NCEP treatment goals for
DL-C and non–HDL-C should be considered in future
ecommendations.
Further study is needed to define the incremental value of
DL-P and LDL size in the setting of LDL-C targets70
g/dl. The preponderance of small, dense LDL-P may
rovide independent information that predicts risk beyond
he traditional lipid profile, particularly in the presence of
he dyslipidemic triad. With regard to high LDL-P and low
DL, there is evidence that the ratio of apoB/apoA-I may
e the strongest predictor of CAD and that such measure-
ent could be incorporated into clinical practice.
opulation-based percentiles for men and women for
poA-I and HDL-C also are available from the Framing-
am Heart Study (36).
Only through well-designed prospective clinical trials will
e be able to determine when lipoprotein heterogeneity
nalysis is justified and how best to use the information. For
ow, selective measurement of apoB might be incorporated
nto clinical practice (when the TG level is above normal),
ith the addition of the apoB/apoA-I ratio and LDL-P
nly when it is likely to change clinical management.
2eprint requests and correspondence: Dr. Peter O. Kwiterovich,
r., University Lipid Clinic, Suite 310, 550 North Broadway
uilding, Baltimore, Maryland 21205. E-mail: pkwitero@
hmi.edu.
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